HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gabriella Fabbrocini Selected Research

Monoclonal Antibodies

7/2023Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study.
6/2023Psoriatic Alopecia and Paradoxical Psoriasis Induced by Adalimumab Successfully Treated with Certolizumab: Clinical, Trichoscopic, and in vivo Reflectance Confocal Microscopy Features.
5/2023Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.
5/2023Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
1/2023Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas.
10/2022Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge.
1/2022New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
1/2022A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
1/2021Cytometric analysis of patients with COVID-19: what is changed in the second wave?
1/2021Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gabriella Fabbrocini Research Topics

Disease

96Psoriasis (Pustulosis Palmaris et Plantaris)
12/2023 - 06/2003
42Atopic Dermatitis (Atopic Eczema)
12/2023 - 06/2003
36COVID-19
02/2023 - 01/2020
31Hidradenitis Suppurativa
10/2023 - 01/2017
26Basal Cell Carcinoma (Rodent Ulcer)
09/2023 - 11/2010
25Acne Vulgaris
02/2023 - 04/2011
22Neoplasms (Cancer)
10/2023 - 05/2007
19Infections
01/2023 - 06/2018
14Alopecia (Baldness)
10/2023 - 01/2019
13Skin Diseases (Skin Disease)
06/2023 - 03/2010
11Pruritus (Itching)
01/2023 - 07/2009
10Skin Neoplasms (Skin Cancer)
09/2023 - 11/2010
10Inflammation (Inflammations)
02/2023 - 04/2011
10Exanthema (Rash)
12/2022 - 05/2012
9Alopecia Areata
12/2023 - 02/2015
9Melanoma (Melanoma, Malignant)
01/2023 - 07/2005
8Eczema
12/2022 - 01/2020
8Erythema
08/2022 - 01/2013
8Cicatrix (Scar)
08/2022 - 01/2010
7Psoriatic Arthritis
06/2023 - 01/2019
7Allergic Contact Dermatitis
01/2023 - 06/2003
5Vitiligo
06/2023 - 01/2021
5Pyogenic Granuloma
01/2022 - 08/2020
4Obesity
04/2023 - 01/2019
4Pain (Aches)
01/2023 - 02/2019
4Candidiasis (Moniliasis)
10/2022 - 06/2018
4Acrodermatitis (Gianotti Crosti Syndrome)
01/2022 - 01/2020
3Hypersensitivity (Allergy)
02/2023 - 01/2019
3Bullous Pemphigoid (Pemphigoid)
01/2023 - 11/2018
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2023 - 01/2022
3Chronic Urticaria
01/2023 - 11/2021
3Dermatitis
11/2022 - 06/2003
3Virus Diseases (Viral Diseases)
06/2022 - 07/2020
3Melanosis (Freckles)
04/2022 - 11/2013

Drug/Important Bio-Agent (IBA)

32dupilumabIBA
12/2023 - 01/2019
21InterleukinsIBA
10/2023 - 01/2018
17Adalimumab (Humira)FDA Link
06/2023 - 05/2019
15ixekizumabIBA
08/2023 - 01/2020
15guselkumabIBA
05/2023 - 01/2020
13Monoclonal AntibodiesIBA
07/2023 - 01/2019
12secukinumabIBA
12/2023 - 01/2019
11sonidegibIBA
09/2023 - 06/2020
11CytokinesIBA
01/2023 - 10/2017
10tildrakizumabIBA
10/2023 - 01/2021
10risankizumabIBA
01/2023 - 11/2020
10HhAntag691IBA
01/2022 - 09/2019
9COVID-19 VaccinesIBA
01/2024 - 01/2022
9apremilastIBA
12/2023 - 02/2019
9Interleukin-17 (Interleukin 17)IBA
01/2023 - 01/2018
8Messenger RNA (mRNA)IBA
01/2024 - 01/2022
7Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2023 - 01/2018
7Ustekinumab (CNTO 1275)FDA Link
05/2023 - 09/2020
7VaccinesIBA
03/2023 - 01/2017
7Immune Checkpoint InhibitorsIBA
12/2022 - 03/2019
6upadacitinibIBA
12/2023 - 01/2022
6Anti-Bacterial Agents (Antibiotics)IBA
01/2023 - 05/2019
6Adrenal Cortex Hormones (Corticosteroids)IBA
01/2023 - 01/2019
6calcipotriene (calcipotriol)FDA LinkGeneric
12/2022 - 01/2020
5ErbB Receptors (EGF Receptor)IBA
07/2023 - 09/2012
5Interleukin-13IBA
07/2023 - 01/2019
5Methotrexate (Mexate)FDA LinkGeneric
06/2023 - 06/2019
5brodalumabIBA
05/2023 - 11/2020
5Biomarkers (Surrogate Marker)IBA
04/2023 - 01/2019
5Minoxidil (Rogaine)FDA LinkGeneric
01/2023 - 07/2009
5betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric
12/2022 - 01/2020
5Tacrolimus (Prograf)FDA LinkGeneric
10/2022 - 08/2019
5Vitamin DFDA LinkGeneric
08/2022 - 06/2020
5SteroidsIBA
07/2022 - 01/2010
5Interleukin-12 (IL 12)IBA
05/2022 - 01/2018
4Biosimilar PharmaceuticalsIBA
01/2023 - 01/2020
4AerosolsIBA
08/2022 - 01/2020
4RetinoidsIBA
08/2022 - 10/2019
4Isotretinoin (Accutane)FDA LinkGeneric
08/2022 - 01/2021
4Hydroxychloroquine (Plaquenil)FDA LinkGeneric
01/2022 - 01/2020
4Proteins (Proteins, Gene)FDA Link
01/2022 - 07/2005
4Salicylic Acid (2 Hydroxybenzoic Acid)FDA LinkGeneric
10/2020 - 11/2013
3Janus Kinase InhibitorsIBA
11/2023 - 01/2020
3bimekizumabIBA
08/2023 - 01/2022
3Immunoglobulin G (IgG)IBA
05/2023 - 01/2021
3AndrogensIBA
02/2023 - 04/2011
3Interleukin-22 (IL-22)IBA
01/2023 - 01/2019
3BNT162 VaccineIBA
01/2023 - 01/2022
3cemiplimabIBA
01/2023 - 01/2022
3Inositol (Myoinositol)IBA
12/2022 - 12/2017
3azelaic acid (Azelex)FDA Link
12/2022 - 04/2021
3Etanercept (Enbrel)FDA Link
10/2022 - 11/2020
3Ointments (Pastes)IBA
10/2022 - 01/2020
3Immunoglobulin A (IgA)IBA
09/2022 - 01/2019
3pembrolizumabIBA
05/2022 - 01/2019

Therapy/Procedure

87Therapeutics
07/2023 - 01/2010
12Drug Therapy (Chemotherapy)
10/2023 - 05/2012
11Biological Therapy
01/2023 - 01/2018
10Radiotherapy
08/2023 - 01/2013
7Phototherapy (Light Therapy)
08/2022 - 01/2015
7Percutaneous Collagen Induction
01/2021 - 01/2010
4Immunotherapy
01/2023 - 01/2017
4Photochemotherapy (Photodynamic Therapy)
01/2022 - 11/2021
4Skin Care
10/2021 - 03/2015
3Tattooing
10/2023 - 12/2021
3Polypharmacy
01/2023 - 04/2020